Real Results: Patient Success Stories from Renew Health's Cardiovascular Prevention Program

What does it actually look like when you catch heart disease before it happens? Not in theory—but in the real lives of people who came to Renew Health with normal-looking numbers and left with a plan that changed their trajectory.

These aren't dramatic deathbed recoveries. They're the quieter victories that don't make the news: plaque that stopped growing, arterial ages that reversed, heart attacks that never happened. These are the patients who got a second look—and what that second look showed.

---

Why Do Patient Stories Matter in Cardiovascular Prevention?

Heart disease is often called a "silent killer" for good reason. Most people who have their first heart attack had no idea it was coming. They felt fine. Their last checkup was unremarkable. Their cholesterol was "borderline but nothing to worry about."

That's the gap between standard care and proactive prevention. Standard care is reactive—it waits for something to go wrong. Preventive cardiology tries to find the problem while there's still time to fix it.

The tool that makes that possible? The CIMT test—a non-invasive ultrasound that measures the thickness and composition of your carotid artery walls, detecting soft plaque years before a calcium scan would ever show it. And the stories below illustrate exactly why that early warning matters.

---

What Does the Science Say Behind These Stories?

Before we get to the patients, it's worth understanding why these outcomes are possible.

Research consistently confirms that carotid IMT measurements predict cardiovascular events—and that those measurements can improve with the right treatment.

In a 2016 community-based prevention study, 324 patients receiving comprehensive cardiovascular risk management showed a 52.7% decrease in soft carotid plaque within two years of starting treatment. CIMT improvements correlated directly with changes in biomarkers like LDL cholesterol, inflammatory markers, and triglycerides. (Cheng HG et al., Arch Med Sci, 2016 — PMID: 27478452)

But there's a catch: monitoring only IMT isn't enough. A landmark study of 349 patients at vascular prevention clinics found that carotid plaque volume progression was a significantly stronger predictor of future cardiovascular events—including MI, stroke, and vascular death—than IMT alone. Patients whose plaque volume progressed over one year had substantially worse outcomes over the following five years. (Wannarong T et al., Stroke, 2013 — PMID: 23735956)

This is why Renew Health tracks both IMT and plaque morphology—soft, heterogeneous, and calcified—year over year. Not just a snapshot, but a trend.

And for risk reclassification, combining plaque thickness with common carotid IMT adds independent predictive value beyond either measure alone, improving how we identify who truly needs aggressive intervention. (Veglia F et al., Atherosclerosis, 2017 — PMID: 28602434)

---

Patient Story #1: Robert — The Marathon Runner Who Almost Missed His Warning Sign

Robert was 58 when he came to Renew Health. By every conventional measure, he was healthy. He ran three to four days a week, had never smoked, and his blood pressure was consistently normal. His primary care doctor had called his last physical "unremarkable."

But Robert had one nagging concern he couldn't shake: his father had died of a heart attack at 61. His older brother had a stent placed at 55. Nobody in his family had any warning. They just dropped.

"I'm fit," Robert told us at his first visit. "But fit and healthy aren't necessarily the same thing, right?"

He was right.

Robert's CIMT revealed heterogeneous plaque in his left carotid artery with an IMT measurement of 0.78 mm—well above the healthy threshold of 0.50 mm. His arterial age calculated to 71 years. He was 58.

His other numbers looked reasonable on the surface: LDL was elevated but not alarming, CRP slightly above normal. Nothing that would have triggered treatment by conventional guidelines.

But Renew Health's team doesn't treat numbers in isolation. With a strong family history and documented plaque, Robert needed an aggressive prevention plan. We initiated statin therapy at a higher intensity than his primary care doctor had ever considered, added targeted supplements to address his elevated inflammatory markers, and adjusted his training to reduce arterial stress.

Twelve months later, Robert's follow-up CIMT showed stabilized plaque with no measurable progression. His arterial age dropped from 71 to 65. His LDL fell by 42%. CRP normalized.

"My dad never got a scan like this," Robert told us at his one-year visit. "I wonder what they would have found."

---

Patient Story #2: Linda — When "Borderline" Turns Out to Mean Something

Linda was 49 when her internist first flagged her cholesterol as "borderline high." She was told to eat better and come back in a year. She did. Numbers were still borderline. Same advice.

For four years, Linda cycled through this routine: borderline cholesterol, lifestyle counseling, no medications, no additional testing. She changed her diet. She started exercising more regularly. Nothing budged her numbers enough to cross the threshold for treatment under standard guidelines.

A colleague mentioned Renew Health. Linda booked an appointment mostly out of frustration.

What we found concerned us immediately. Linda's CIMT showed diffuse soft plaque in both carotid arteries with a maximum IMT of 0.91 mm. Her arterial age: 68. She was 49.

Her lipid panel revealed more when we dug deeper: her LDL particle count was markedly elevated even though her standard LDL numbers had seemed only borderline. Her apolipoprotein B was high. Her TG/HDL ratio suggested significant insulin resistance. The "borderline" label had masked a much more concerning picture.

Linda had been treatable for years. She just hadn't been tested thoroughly enough.

We initiated combination lipid-lowering therapy, addressed her insulin resistance through dietary modification and a targeted supplement protocol, and scheduled yearly CIMT monitoring.

At her 18-month follow-up, Linda's soft plaque had decreased significantly—regression confirmed on ultrasound. Her arterial age dropped from 68 to 60. Her LDL particle count fell by more than 50%.

"Nobody ever looked this closely before," she said. "I spent four years being told I was fine."

---

Patient Story #3: James — The "Healthy" 44-Year-Old

James was 44. No family history of heart disease. Non-smoker. Normal weight. He came to Renew Health almost on a whim—his wife had heard about CIMT testing and bought a program as a gift for his birthday.

"She's more worried about my heart than I am," he told us.

His CIMT came back with early soft plaque in his right internal carotid—IMT measuring 0.62 mm, arterial age 52. Not yet alarming, but not normal either. At 44, it was a clear early signal.

His bloodwork revealed the driver: markedly elevated lipoprotein(a)—a genetic risk factor that affects roughly 20% of the population and is largely invisible to standard cholesterol panels. Lp(a) is largely genetic and can't be meaningfully reduced through diet. James had never been tested for it. Neither he nor his doctors had any reason to think his heart was anything but healthy.

James's intervention was targeted: medications to aggressively manage LDL and prevent further plaque development, with close monitoring of Lp(a) levels as emerging therapies continue to develop. We also started him on a structured cardiovascular exercise program.

At his one-year check: no plaque progression. Arterial age held steady at 52—meaning at 45, his arteries weren't aging. That's the goal.

"I probably would have hit 55 or 60 and had my first event with no warning at all," James said. "Nobody would have caught this for another decade."

---

What Do These Stories Have in Common?

Three different patients. Three different risk profiles. Three different ages. But they share something important:

1. Standard care missed them. All three had either normal or borderline results by conventional measures. None would have been flagged for aggressive prevention under standard guidelines.

2. CIMT found what bloodwork couldn't. Plaque was already forming—soft, dangerous, actionable—in people who had been told they were fine.

3. Early detection led to real change. Not just reassurance, but measurable reversal: shrinking plaque, lower arterial age, normalized biomarkers.

4. The window is the point. Once plaque calcifies or ruptures, the options narrow. Catching it in the soft phase is when intervention has the most impact.

---

Who Is This Testing For?

You don't have to be sick to benefit from this kind of testing. You don't have to have chest pain or a family history of dramatic cardiac events.

You might be a candidate for comprehensive cardiovascular screening if you:

• Are over 40 and haven't had thorough cardiovascular risk assessment
• Have "borderline" numbers that never quite trigger treatment
• Have a family history of early heart attack or stroke
• Feel healthy but want to confirm what's actually happening inside your arteries
• Want to track whether your current lifestyle is working—or not

The Renew Health approach starts with a CIMT test—the same non-invasive, radiation-free ultrasound that found the plaque in Robert, Linda, and James's arteries before it became a crisis.

---

What Makes the Renew Health Difference?

What makes these outcomes possible isn't magic. It's rigor.

• Advanced imaging — We measure soft, heterogeneous, and calcified plaque separately, not just IMT alone
• Yearly tracking — We watch trends over time, not just a single snapshot
• Complete biomarker panels — LDL particles, apolipoprotein B, Lp(a), inflammatory markers, insulin sensitivity—the full picture
• Personalized plans — Treatment intensity matched to your actual risk, not a population average

Our clinical team has over 20 years of experience in cardiovascular prevention. The goal isn't to find problems—it's to find them early enough to matter.

---

Ready to See Your Picture?

Robert, Linda, and James didn't know what their arteries looked like until they asked. Now they do. And they know whether they're getting better.

That knowledge—specific, visual, actionable—is available to you too.

Take the next step:

• Learn more about CIMT testing at Renew Health
• See our programs and pricing
• Schedule a consultation to find out if CIMT is right for you

Because a heart attack that never happens doesn't make headlines. But it should.

---

References

1. Cheng HG, et al. Effect of comprehensive cardiovascular disease risk management on longitudinal changes in carotid artery intima-media thickness in a community-based prevention clinic. Arch Med Sci. 2016;12(4):716–722. https://pubmed.ncbi.nlm.nih.gov/27478452/

2. Wannarong T, et al. Progression of carotid plaque volume predicts cardiovascular events. Stroke. 2013;44(7):1859–1865. https://pubmed.ncbi.nlm.nih.gov/23735956/

3. Veglia F, et al. Carotid plaque-thickness and common carotid IMT show additive value in cardiovascular risk prediction and reclassification. Atherosclerosis. 2017;263:412–419. https://pubmed.ncbi.nlm.nih.gov/28602434/

4. Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596–e646. https://pubmed.ncbi.nlm.nih.gov/30879355/